The 36-month beta value for DRIO is at 1.70. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DRIO is 23.91M, and currently, shorts hold a 5.70% of that float. The average trading volume for DRIO on April 23, 2024 was 128.98K shares.
DRIO) stock’s latest price update
DarioHealth Corp (NASDAQ: DRIO) has experienced a rise in its stock price by 13.79 compared to its previous closing price of 1.16. However, the company has seen a gain of 15.79% in its stock price over the last five trading days. Seeking Alpha reported 2023-10-03 that DarioHealth has experienced a disappointing year with stalled revenue growth and a decline in new customer wins. However, H2/23 and FY24 are expected to bring improved financials, including revenue growth, expanded gross margins, and declining operating expenses. The company’s competitive advantages include a customer-friendly platform, a multi-condition platform, and partnerships with important industry players.
DRIO’s Market Performance
DarioHealth Corp (DRIO) has experienced a 15.79% rise in stock performance for the past week, with a -9.59% drop in the past month, and a -38.89% drop in the past quarter. The volatility ratio for the week is 10.65%, and the volatility levels for the past 30 days are at 12.97% for DRIO. The simple moving average for the past 20 days is -2.26% for DRIO’s stock, with a -41.51% simple moving average for the past 200 days.
Analysts’ Opinion of DRIO
Many brokerage firms have already submitted their reports for DRIO stocks, with Alliance Global Partners repeating the rating for DRIO by listing it as a “Buy.” The predicted price for DRIO in the upcoming period, according to Alliance Global Partners is $8.75 based on the research report published on May 13, 2022 of the previous year 2022.
Cowen, on the other hand, stated in their research note that they expect to see DRIO reach a price target of $31. The rating they have provided for DRIO stocks is “Outperform” according to the report published on April 22nd, 2021.
Stifel gave a rating of “Buy” to DRIO, setting the target price at $30 in the report published on March 23rd of the previous year.
DRIO Trading at -20.77% from the 50-Day Moving Average
After a stumble in the market that brought DRIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.18% of loss for the given period.
Volatility was left at 12.97%, however, over the last 30 days, the volatility rate increased by 10.65%, as shares sank -8.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.96% lower at present.
During the last 5 trading sessions, DRIO rose by +15.79%, which changed the moving average for the period of 200-days by -65.45% in comparison to the 20-day moving average, which settled at $1.3440. In addition, DarioHealth Corp saw -23.26% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for DRIO
Current profitability levels for the company are sitting at:
- -2.75 for the present operating margin
- 0.29 for the gross margin
The net margin for DarioHealth Corp stands at 0.04. The total capital return value is set at -0.67. Equity return is now at value -79.57, with -50.99 for asset returns.
Based on DarioHealth Corp (DRIO), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at -1.06. The debt to equity ratio resting at 0.49. The interest coverage ratio of the stock is -33.61.
Currently, EBITDA for the company is -50.84 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 1.54. The receivables turnover for the company is 5.98for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.77.
Conclusion
In conclusion, DarioHealth Corp (DRIO) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
